Kamada (KMDA) Competitors $7.78 +0.03 (+0.39%) Closing price 07/14/2025 04:00 PM EasternExtended Trading$7.76 -0.02 (-0.26%) As of 07/14/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KMDA vs. ADPT, SRPT, TARS, IMCR, ARQT, SPRY, SDGR, OCUL, VERA, and BHVNShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), Tarsus Pharmaceuticals (TARS), Immunocore (IMCR), Arcutis Biotherapeutics (ARQT), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Its Competitors Adaptive Biotechnologies Sarepta Therapeutics Tarsus Pharmaceuticals Immunocore Arcutis Biotherapeutics ARS Pharmaceuticals Schrodinger Ocular Therapeutix Vera Therapeutics Biohaven Adaptive Biotechnologies (NASDAQ:ADPT) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Do analysts rate ADPT or KMDA? Adaptive Biotechnologies currently has a consensus target price of $10.57, suggesting a potential downside of 8.47%. Kamada has a consensus target price of $13.00, suggesting a potential upside of 67.10%. Given Kamada's higher probable upside, analysts plainly believe Kamada is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Kamada 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is ADPT or KMDA more profitable? Kamada has a net margin of 9.60% compared to Adaptive Biotechnologies' net margin of -74.84%. Kamada's return on equity of 6.31% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-74.84% -62.79% -24.55% Kamada 9.60%6.31%4.43% Which has stronger earnings & valuation, ADPT or KMDA? Kamada has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M9.80-$159.49M-$0.96-12.03Kamada$167.24M2.68$14.46M$0.2926.83 Does the media prefer ADPT or KMDA? In the previous week, Adaptive Biotechnologies had 10 more articles in the media than Kamada. MarketBeat recorded 11 mentions for Adaptive Biotechnologies and 1 mentions for Kamada. Kamada's average media sentiment score of 1.87 beat Adaptive Biotechnologies' score of 0.56 indicating that Kamada is being referred to more favorably in the news media. Company Overall Sentiment Adaptive Biotechnologies Positive Kamada Very Positive Which has more risk & volatility, ADPT or KMDA? Adaptive Biotechnologies has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Kamada has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Do institutionals and insiders have more ownership in ADPT or KMDA? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryKamada beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$447.39M$2.95B$5.54B$9.14BDividend YieldN/A2.43%5.01%4.00%P/E Ratio26.8321.1628.6919.45Price / Sales2.68184.72372.4779.78Price / Cash15.7741.0524.7227.47Price / Book1.737.758.215.58Net Income$14.46M-$55.05M$3.19B$252.81M7 Day Performance1.04%9.69%3.60%2.11%1 Month Performance13.08%13.80%9.61%11.87%1 Year Performance34.60%3.55%30.04%16.61% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada4.1283 of 5 stars$7.78+0.4%$13.00+67.1%+25.3%$447.39M$167.24M26.83360ADPTAdaptive Biotechnologies2.8815 of 5 stars$11.74-0.5%$10.57-10.0%+188.8%$1.79B$178.96M-12.23790SRPTSarepta Therapeutics4.7044 of 5 stars$17.32-5.0%$60.88+251.5%-87.4%$1.79B$1.90B-6.441,372Trending NewsTARSTarsus Pharmaceuticals1.7539 of 5 stars$39.93-3.0%$66.67+67.0%+41.1%$1.73B$182.95M-14.6350Positive NewsIMCRImmunocore1.4553 of 5 stars$32.41-1.8%$58.89+81.7%-10.7%$1.66B$310.20M-75.37320ARQTArcutis Biotherapeutics1.2929 of 5 stars$13.39-3.1%$18.80+40.4%+49.7%$1.65B$196.54M-12.88150News CoverageInsider TradeSPRYARS Pharmaceuticals2.8369 of 5 stars$17.09+3.5%$31.00+81.4%+57.7%$1.62B$89.15M-106.8190SDGRSchrodinger1.8652 of 5 stars$20.63-2.3%$33.25+61.2%-5.6%$1.55B$207.54M-7.84790Analyst ForecastOCULOcular Therapeutix3.9453 of 5 stars$9.61-0.1%$17.33+80.4%+38.6%$1.53B$63.72M-8.36230Positive NewsVERAVera Therapeutics4.1524 of 5 stars$22.97-4.3%$65.00+183.0%-35.1%$1.53BN/A-7.6640BHVNBiohaven3.0675 of 5 stars$13.81-5.6%$58.46+323.3%-62.8%$1.49BN/A-1.48239 Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Sarepta Therapeutics Alternatives Tarsus Pharmaceuticals Alternatives Immunocore Alternatives Arcutis Biotherapeutics Alternatives ARS Pharmaceuticals Alternatives Schrodinger Alternatives Ocular Therapeutix Alternatives Vera Therapeutics Alternatives Biohaven Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KMDA) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KMDA Stock Alerts